Celldex Therapeutics doesn't want to get personal about cancer. While mnay other biotechs are pursuing personalized (i.e., patient-specific) cancer therapies, the company instead is developing products that can be used off-the-shelf. A subsidiary of Medarex, the firm has technology designed to stimulate the immune system using a proprietary cloned antibody. Celldex's lead product candidate, HCG-VAC, is a cancer vaccine being developed to treat colorectal, pancreatic, bladder, and breast cancers. The company has announced plans to go public; parent Medarex will own 70% of Celldex after it makes its debut on Nasdaq.